Tools
Tools
Xie, Chunfang, Albulescu, Laura-Oana 
ORCID: https://orcid.org/0000-0001-6563-9217, Bittenbinder, Mátyás A, Somsen, Govert W, Vonk, Freek J, Casewell, Nicholas ORCID: https://orcid.org/0000-0002-8035-4719 and Kool, Jeroen
(2020)
'Neutralizing Effects of Small Molecule Inhibitors and Metal Chelators on Coagulopathic Snake Venom Toxins.'. Biomedicines, Vol 8, Issue 9, E297.
|
Text
Xie et al 2020_Neutralizing effects of small molecule inhibitors_Biomedicines-Aug-20.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview |
Abstract
Animal-derived antivenoms are the only specific therapies currently available for the treatment of snake envenoming, but these products have a number of limitations associated with their efficacy, safety and affordability for use in tropical snakebite victims. Small molecule drugs and drug candidates are regarded as promising alternatives for filling the critical therapeutic gap between snake envenoming and effective treatment. In this study, by using an advanced analytical technique that combines chromatography, mass spectrometry and bioassaying, we investigated the effect of several small molecule inhibitors that target phospholipase A (varespladib) and snake venom metalloproteinase (marimastat, dimercaprol and DMPS) toxin families on inhibiting the activities of coagulopathic toxins found in snake venoms. The venoms of , , and , which are known for their potent haemotoxicities, were fractionated in high resolution onto 384-well plates using liquid chromatography followed by coagulopathic bioassaying of the obtained fractions. Bioassay activities were correlated to parallel recorded mass spectrometric and proteomics data to assign the venom toxins responsible for coagulopathic activity and assess which of these toxins could be neutralized by the inhibitors under investigation. Our results showed that the phospholipase A-inhibitor varespladib neutralized the vast majority of anticoagulation activities found across all of the tested snake venoms. Of the snake venom metalloproteinase inhibitors, marimastat demonstrated impressive neutralization of the procoagulation activities detected in all of the tested venoms, whereas dimercaprol and DMPS could only partially neutralize these activities at the doses tested. Our results provide additional support for the concept that combinations of small molecules, particularly the combination of varespladib with marimastat, serve as a drug-repurposing opportunity to develop new broad-spectrum inhibitor-based therapies for snakebite envenoming.
| Item Type: | Article |
|---|---|
| Subjects: | QV Pharmacology > Hematologic Agents > QV 180 Hematologic agents QV Pharmacology > Heavy Metals. Gases > QV 290 Heavy metals and their compounds WD Disorders of Systemic, Metabolic or Environmental Origin, etc > Animal Poisons > WD 410 Reptiles |
| Faculty: Department: | Biological Sciences > Department of Tropical Disease Biology |
| Digital Object Identifer (DOI): | https://doi.org/10.3390/biomedicines8090297 |
| Depositing User: | Mary Creegan |
| Date Deposited: | 25 Aug 2020 11:34 |
| Last Modified: | 25 Aug 2020 11:34 |
| URI: | https://archive.lstmed.ac.uk/id/eprint/15412 |
Statistics
Actions (login required)
 |
Edit Item |